

Table 1: Table 3 Efficacy/effectiveness and safety results in phase III clinical trials

| Author, Year               | Sample size | Intervention | Target | Comparator                                  | Efficacy         | Comparison of intervention and comparator                                      | Safety                      | Safety in the intervention   |
|----------------------------|-------------|--------------|--------|---|------------------|--|-----------------------------|--|
| Sidiqi, 2023 [61]          | 208         | Cilta-cel    | BCMA   | PVd or DPd                                  | PFS              | HR: 0.26; $P < 0.0001$   | CRS, ICANS                  | CRS: 76% any grade, 1% Grade 3; ICANS: 5% any grade, 0% Grade 3/4; Other neurotoxicities: 17% any grade, 2% Grade 3/4 (including cranial nerve paralysis 9%, peripheral neuropathy 3%, and one case of Grade 1 movement/neurocognitive-related AE) |
| Rodriguez Otero, 2023 [62] | 386         | Ide-cel      | BCMA   | Standard regimens (five different regimens) | PFS              | HR for disease progression or death: 0.49 (95% CI, 0.38 to 0.65; $P < 0.001$ ) | Grade 3 or 4 adverse events | CRS: 93%   |
| San-Miguel, 2024 [63]      | 419         | Cilta-cel    | BMCA   | SOC   | Overall survival | 30mo OS 76.4% vs 63.8% (HR 0.55)   | CRS, ICANS                  | G3 CRS: 1%, ICANS: 0%  |
| Ailawadh, 2024 [57]        | 386         | Ide-cel      | BMCA   | SOC   | mPFS             | mPFS 13.3 vs 4.4 mo (HR 0.49)  | CRS, ICANS                  | G3 CRS: 0%, ICANS: 2%  |

Table 2: Table 4 Infusion schedule, target dose, and in-vivo persistence

| Product   | Infusion schedule | Target dose                                  | Reported in vivo persistence* |
|-----------|-------------------|--|-------------------------------|
| Cilta-cel | Single            | $0.75 \times 10^8$ CAR <sup>+</sup> cells/kg | Median 277 days               |

Continued on next page

Table 2: Table 4 Infusion schedule, target dose, and in-vivo persistence (Continued)

| <b>Product</b> | <b>Infusion schedule</b> | <b>Target dose</b>                           | <b>Reported in vivo persistence*</b> |
|----------------|--------------------------|--|--------------------------------------|
| Ide-cel        | Single                   | $150 \times 10^6$ to $450 \times 10^6$ cells | Median 4.2 months                    |
| CT103A         | Single                   | $1.0 \times 10^8$ cells/kg                   | Detectable 12 months (61%)           |
| LCAR-B38M      | 3 split (20/30/50%)      | $0.5 \times 10^8$ cells/kg                   | Median 8 months                      |
| ALLO-715       | Single                   | $320 \times 10^6$ cells                      | < 28 days                            |